Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Skin Cancer

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Eur J Cancer

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV

doi: 10.1016/j.ejca.2025.115381

Lung, Respiratory and Thoracic Cancer

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

J Clin Oncol

Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA, IMpower010 Study Investigators

doi: 10.1200/JCO-24-01681

Lung, Respiratory and Thoracic Cancer

Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients

Lung Cancer

Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K

doi: 10.1016/j.lungcan.2025.108104

Lung, Respiratory and Thoracic Cancer

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Lung Cancer (Auckl)

Luo FX, Arter Z, Ou SI, Nagasaka M

doi: 10.2147/LCTT.S520833

Skin Cancer

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

J Clin Oncol

Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E

doi: 10.1200/JCO-24-02776

Skin Cancer

Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma

Ann Oncol

Kähler KC, Hassel JC, Ziemer M, Rutkowski P, Meier F, Flatz L, Gaudy-Marqueste C, Zimmer L, Santinami M, Russano F, von Wasielewski I, Eigentler TK, Maio M, Zalaudek I, Haferkamp S, Quaglino P, Welzel J, Röcken C, Enk A, Simon JC, Świtaj T, Garzarolli M, Amaral T, Malissen N, Livingstone E, Elia G, Covelli A, Lorizzo K, Neri D, Mulatto S, Parca A, Pizzichi B, Ascierto PA, Garbe C, Robert C, Schadendorf D, Hauschild A

doi: 10.1016/j.annonc.2025.06.014

Skin Cancer

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Eur J Cancer

Boutros A, Taylor AM, Li I, Adegoke NA, Wong T, Varey AHR, Shannon KF, Ch'ng S, Saw RPM, Pennington T, Stretch J, Spillane A, van Akkooi ACJ, Scolyer RA, Pires da Silva I, Carlino MS, Long GV, Lo SN, Menzies AM

doi: 10.1016/j.ejca.2025.115782

Lung, Respiratory and Thoracic Cancer

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

JAMA Oncol

Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, Wang X, Mayoral Penalva M, Ginsberg M, Sholl LM, Nishino M, Di Federico A, Shaverdian N, Bott M, Santo V, Rendina E, Trisolini R, Ramella S, Gallina F, Melis E, Buglioni S, Minuti G, Landi L, Ugalde Figueroa PA, Shaw AT, Chaft J, Awad MM, Cappuzzo F

doi: 10.1001/jamaoncol.2025.1115

Related content

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer